CLINICAL_TRIALS
trial_result
· 2016-04-15
Clinical Trial Update: Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Summary
A Phase 2 trial evaluating vorinostat plus FND in relapsed or refractory mantle cell lymphoma was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Samsung Medical Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED